Ingen Takes Next Step With ISO 13485 Certification for China, Japan, Canada and Europe

YUCAIPA, Calif., June 10, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc.
(Pink Sheets:IGNT), a leading Medical Device Manufacturer focused in the $8
Billion global Respiratory Markets for the growing ageing population and
emerging markets for Home (DME), Hospital and Aviation Industries announced
today that the company has commenced ISO 13485 staff training this week with the
Emergo Group.

The company has signed contracts with the Austin-Texas based Emergo Group to
prepare, train and coordinate all International Standard Organization (ISO)
13485 certifications to market and sell Oxyview in China, Japan, Canada and the
European Community. In addition to the ISO certification requirement, the
contracts also include the CE Mark required to sell Oxyview in Europe.

The training and document specialist with the Emergo Group, Cheryl Fisher, has
been training the Ingen management and staff on ISO certification and document
requirement procedures. The ISO certification process will take approximately
3-6 months. ISO is a network of the national standards institutes of 161
countries, one member per country, with a Central Secretariat in Geneva,
Switzerland, that coordinates the system. ISO is a non-governmental organization
that forms a bridge between the public and private sectors. On the one hand,
many of its member institutes are part of the governmental structure of their
countries, or are mandated by their government. On the other hand, other members
have their roots uniquely in the private sector, having been set up by national
partnerships of industry associations. Therefore, ISO enables a consensus to be
reached on solutions that meet both the requirements of business and the broader
needs of society.

"Ingen has invested tens of thousands of dollars with the Emergo Group to insure
ISO 13485 certification in countries that have a strong interest and large
revenue potential for our Oxyview product, inclusive of our new Oxyview-Cannula
product being introduced in the next week," stated Scott R. Sand, Chief
Executive Officer and Chairman of the Board.

About Oxyview:

Oxyview is a proprietary medical device with U.S. issued patents that stands
alone in an increasing patient home oxygen therapy market while there are 23
million patients diagnosed with chronic obstructive pulmonary disease (COPD) in
the United States, according to the World Health Organization, and another 12
million patients that are undiagnosed in the U.S. COPD is the fifth leading
cause of death in the U.S. and there are 600 million COPD patients worldwide
where in most cases, COPD is either the first or second leading cause of death
in other countries. The majority of COPD patients require continued home oxygen
therapy, which includes all of the required equipment supplied by the home (DME)
provider. With the new regulations for oxygen reimbursement in the U.S., the
home (DME) providers need to cut costs to stay in business. Oxyview provides a
substantial savings as a result of decreasing the number of service calls for
the home (DME) provider. Oxyview is a pneumatic metering device that displays
oxygen flow near the patient. The Oxyview flow meter easily and quickly installs
on to the oxygen tubing nearest the patient where oxygen flow matters the most.
Without the Oxyview, patients cannot confirm oxygen flow, and as a result there
is an increase in anxiety and the patient calls the home (DME) provider with
concerns. Oxyview also allows the home (DME) provider to trouble-shoot other
equipment problems over the telephone which eliminates an on-site visit with the
patient. More important, the Oxyview provides the patient with more assurance
that they are receiving adequate and prescribed oxygen flow. The Oxyview cost
less than a single service call.

www.ingen-tech.com

http://www.iso.org/iso/home.htm

http://www.emergogroup.com/

The Ingen Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes
forward-looking statements. While these statements are made to convey to the
public the company's progress, business opportunities and growth prospects,
readers are cautioned that such forward-looking statements represent
management's opinion. Whereas management believes such representations to be
true and accurate based on information and data available to the company at this
time, actual results may differ materially from those described. The company's
operations and business prospects are always subject to risk and uncertainties.
Important factors that may cause actual results to differ are and will be set
forth in the company's periodic filings with the U.S. Securities and Exchange
Commission.

-0-
CONTACT: Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
www.INGEN-TECH.COM